The authors describe the use of modified baculoviruses containing mammalian expression cassettes (BacMam technology) in steroid nuclear receptor reporter assays designed for screening and profiling agonist and antagonist compounds. Baculoviruses were constructed that express full-length human genes for mineralocorticoid receptor (MR), glucocorticoid receptor (GR), progesterone receptor A (PR-A), and progesterone receptor B (PR-B) from the cytomegalovirus immediate early promoter. A virus carrying the mouse mammary tumor virus-firefly luciferase (MMTV-Luc) cassette was generated to provide a suitable reporter construct. Feasibility studies with BacMam-MR in single-dose tests of 1000 compounds showed high correlation to the standard transfection-based assay results. Likewise, in dose-response experiments, BacMam-based assays for GR and PR-B produced potency and efficacy values similar to transfection assay results. At various receptor/reporter ratios, the BacMam assays showed good flexibility, demonstrating consistent signal-to-background (S/B) ratios and compound potencies. Increasing transduction time from 24 to 48 h provided no benefit, actually reducing overall assay performance as measured by S/B and Z′ values. The BacMam technology was applied in studies of isoforms PR-A and PR-B, which showed similar responses to a series of agonists. Taken together, the results demonstrate the utility of steroid nuclear receptor BacMam constructs for compound screening procedures with high reproducibility, reduced turnaround time, and lower cost. (Journal of Biomolecular Screening 2005:715-724) 
INTRODUCTION

R
APID ADVANCES IN GENOMICS AND PROTEOMICS have led to the identification of numerous target proteins with potential disease associations. Combinatorial chemistry has concomitantly produced large numbers of compounds with potential therapeutic applications. Although progress in miniaturized automation technology has allowed for improved interrogation of these compounds, the dramatic growth of both chemical libraries and targets has combined to challenge the capacity of screening assays. As a consequence, continued improvements in the time to develop and execute screening procedures are required. 1, 2 Identification of a lead molecule involves a multistep process, typically including high-throughput screening (HTS) followed by secondary assays for confirmation of hits. Although the decision to implement a particular assay format at a given stage will depend on factors such as throughput, cost, and physiological relevance, it is often desirable to include cell-based functional assays in the screening process. Cell-based assays may provide information about a compound not discernable from a biochemical assay, such as mode of action as an agonist or antagonist, ability to cross the cell membrane, or toxicity profile. 3 Nuclear receptor cell-based assays are often configured to monitor ligand-modulated reporter gene expression. As transcription factors, nuclear receptors directly control gene expression by binding to distinct DNA motifs known as hormone response elements that are situated within promoter regions. 4 For instance, the steroid nuclear receptors can interact with hormone response elements in mouse mammary tumor virus (MMTV) promoter sequences. 5 In most cases, ligand binding to a nuclear receptor allows the recruitment of coactivator complexes possessing histone acetyltransferase activity, leading to chromatin decondensation and transcription initiation. 5, 6 These properties have been exploited in the design of nuclear receptor reporter assays. By linking a response element with a reporter gene such as luciferase or alkaline phosphatase, the cellular activity of a nuclear receptor may be monitored in the presence or absence of its cognate ligand. [7] [8] [9] Indeed, cell lines carrying stably integrated reporter constructs have proven useful for HTS endeavors. 3, 10, 11 However, stable cell lines have some drawbacks: they take several months to generate and characterize, 12, 13 they lack the flexibility that transient expression systems offer, and they may demonstrate reduced assay performance with increased passage because of genetic or epigenetic modifications of the integrated construct. 14, 15 Conversely, transient transfection procedures allow the introduction of assorted reporter, receptor, and cofactor plasmids into a cell line of choice, thereby providing flexibility in the assay format. Commercially available liposomal reagents generally offer favorable transfection efficiencies and reproducibility. 16 Nevertheless, transient transfection procedures also have specific drawbacks: they can prove costly for large-scale screening efforts, are not easily automated, and sometimes exhibit unacceptable cytotoxicity.
BacMam technology, the use of recombinant baculoviruses for gene delivery into mammalian cells, offers an alternative to stable cell lines and liposomal transfection procedures. 12, 17 Baculoviruses engineered to carry genes under the control of mammalian promoters have proven capable of transducing a broad range of cell types. These include an assortment of commonly used cell lines such as HepG2, CHO, CV-1, HeLa, and HEK293 [18] [19] [20] ; primary cells such as kidney, liver, neural, and osteal cells [21] [22] [23] [24] ; and other cell lines traditionally difficult to transfect such as Saos-2. 25, 26 For cellbased assay development, BacMam technology retains the flexibility of transient transfection procedures while offering several other compelling features, including low cost, low toxicity, titratable expression, and amenability to automation. 17, 27 Previous reports have suggested the potential utility of recombinant baculoviruses in drug-screening procedures for ion channels 27 and estrogen receptors. 26 In this communication, we evaluate several steroid nuclear receptor assays using recombinant baculovirus constructs, comparing results to those obtained by DNA transfection. Assays are measured against performance criteria, including reproducibility of compound activity, signal-to-background (S/B) ratios, and Z′ values. The use of BacMam technology also enables us to explore assay parameters having reduced turnaround time.
MATERIALS AND METHODS
Shuttle plasmid construction
Plasmid pFastBac-Mam-1 (pFBM) is a derivative of pFastBac (Invitrogen) and carries the CMV-IE1 promoter element upstream of a multiple cloning site (MCS). 19 Inserts were subcloned into pFBM at the MCS to generate shuttle plasmids pFBM-human mineralocorticoid receptor (pFBM-MR), pFBM-human glucocorticoid receptor (pFM-GR), pFBM-human progesterone receptor A (pFBM-PR-A), pFBM-human progesterone receptor B (pFBM-PR-B), and pFBM-MMTV-firefly luciferase (pFBM-MMTVLuc). Full-length sequences for human MR, GR, PR-B, and PR-A were generated with standard PCR procedures using primers carrying restriction sites. 28 MR was subcloned into the MCS of pFBM as a KpnI/XhoI fragment, GR as a NotI/ApaI fragment, and PR-B and PR-A as KpnI/NotI fragments using standard molecular techniques, including restriction digestion and ligation. 29 Sequences for PR-B (2.8 kb) and its shorter isoform, PR-A (2.3 kb), were generated by PCR using the same source plasmid DNA (pBK-hPR-B). To generate PR-A, a 5′ PCR primer was designed to reintroduce an ATG start site at base 492 of the PR-B sequence, thereby replacing the coding sequence for alanine with methionine. The same 3′ PCR primer was used in the generation of both PR-B and PR-A. Plasmid pFBM-MMTV-Luc was generated by replacing the cytomegalovirus (CMV) promoter in pFBM with the MMTV promoter, followed by insertion of the firefly luciferase gene as a HindIII/XbaI fragment. The integrity of each construct was confirmed by diagnostic restriction digestion and by sequencing.
Recombinant baculovirus generation
Recombinant baculoviruses were generated as described previously 19 using the Bac-to-Bac system (Invitrogen) with each shuttle plasmid. Briefly, recombinant virus is generated by site-specific transposition of shuttle plasmid insert sequences into target site sequences on a baculovirus genomic vector carried in Escherichia coli DH10Bac competent cells (Invitrogen). Viruses used in the assays were scaled up in Spodoptera frugiperda (Sf9) cells grown in serum-free ExCell 420 insect cell culture medium (JRH Biosciences). Virus stocks were supplemented with 5% charcoal/ dextran-stripped, delipidated fetal calf serum (FCS), purchased from Sigma, and heat inactivated at 62°C for 35 min prior to use. Virus titer was determined by plaque assay on Sf9 cells according to standard protocol. 30 
Cell culture
African green monkey kidney cell line CV-1 (ATCC CCL-70) and human breast carcinoma cell line T47D (ATCC HTB-133) were grown at 37°C in a humidified incubator with 5% CO 2 . Cells were grown in maintenance media composed of the following: Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal calf serum, 2 mM glutamine, and penicillin/ streptomycin. Cells for experimental use were grown in assay media composed of the following: phenol red-free DMEM supplemented with 10% charcoal-stripped, dextran-treated FCS; glutamine; and penicillin/streptomycin. Charcoal-stripped, dextrantreated FCS was used with assay media because of the presence of steroid receptor agonists present in full serum, which results in high basal activity and a small S/B. Charcoal-stripped, dextrantreated FCS was purchased from Hyclone; all other cell culture reagents were from Invitrogen.
Compound handling and assay plates
Compounds were reconstituted in DMSO at 0.1 mM or 1 mM. In all experiments, the final assay concentration of DMSO was 1%. For single-dose experiments, 0.5 µL of each compound was stamped to columns 1 to 22 of solid white 384-well assay plates (NUNC, catalog #164564) using a Beckman FX. For 11-point dose-response experiments, compounds in columns 1 and 12 were 4-fold serially diluted across the plate in DMSO and then stamped to 384-well assay plates in a similar manner. For data normalization and statistical evaluation of assay performance by Z′ calculation, 31 0.5 µL per well of appropriate controls was stamped to columns 23 (DMSO) and 24 (standard positive control) for each assay plate. Upon addition of 50 µL of cells (10,000/well), the final concentration for single-dose experiments was 1 µM. The starting concentration for dose-response experiments was either 1 µM or 10 µM. Standard agonists for MR, GR, and PR were aldosterone, dexamethasone, and progesterone, respectively. The standard antagonist for PR was mifepristone (RU-486).
Transfection and baculovirus transduction
Three days prior to transfection or baculovirus transduction, cells were cultured in assay media. Transfections of cells (70%-80% confluent) in T-225 flasks were performed overnight in Opti-MEM (Invitrogen) using FuGENE (Roche) according to the manufacturer's specifications. Each transfection contained 4.8 µg of pcDNA3.1-based or pSG5-based steroid receptor plasmid DNA, 9.6 µg of reporter plasmid DNA, and 25.6 µg of pBluescript ("filler" DNA) per T-225 flask. The following day, transfected cells were detached from flasks using trypsin, and cell densities were determined with a Sysmex cell counter or hemocytometer. Cells diluted in assay media were distributed to 384-well assay plates at 10,000 cells per well using a Titertek Multidrop.
For baculovirus transductions, cells grown in T-225 flasks were treated with trypsin and resuspended in assay media, and cell densities were determined. For all assays, cells were immediately seeded at 10,000/well in the presence of baculovirus in 384-well assay plates and incubated overnight. For PR antagonist mode assays, progesterone was added to a final concentration of 4 nM (EC 80 ) immediately prior to seeding of cells onto assay plates containing test compounds. Addition of 4 nM progesterone after a 2-h incubation of cells in the presence of test compounds did not alter their observed antagonist activity.
Firefly luciferase assays
Following DNA transfections or baculovirus transductions, 20 µL of Steady-Glo reagent (Promega) was added to each well of the assay plates using a Multidrop. Plates were incubated for 10 min to ensure complete cell lysis and read in a TopCount (Packard). A summary of transfection and BacMam assay procedures is presented (Fig. 1) .
Western blot analysis of PR constructs
Human U-2OS osteosarcoma cells (ATCC HTB-96) were transduced for 24 h at a multiplicity of 200 virus particles per cell with BacMam-PR-B, BacMam-PR-A, or a negative control virus (BacMam-GFP). Whole-cell extracts were separated on NuPAGE 4% to 12% gradient gels and analyzed by Western blotting using standard methodology. 29 Blots were probed with monoclonal PR antibody (AB-52) purchased from Santa Cruz, and luminescent signal was generated with an ECL detection reagent kit (Amersham Biosciences). Lysis was confirmed by visualization of cellular proteins on Coomasie-stained gels (data not shown).
RESULTS
BacMam compares favorably to transfection in single-dose assays
To gain a sufficiently broad characterization of recombinant baculovirus constructs in luciferase reporter assays, we examined the performance of BacMam-MR in single-dose experiments in which 1064 compounds were assayed, each at a concentration of 1 µM. These compounds were from a targeted array specifically designed for steroid nuclear receptors. T47D cells were cotransduced with BacMam-MR (50 virus particles per cell) and BacMam-MMTV-Luc (200 virus particles per cell), and cells were seeded onto duplicate 384-well compound plates. A DNA transfection procedure with FuGENE was performed in parallel. For each compound, mean luminescence counts were expressed as a percentage of aldosterone-stimulated signal (Fig. 2) . In this experiment, BacMam-MR transduction produced results with high correlation to the standard DNA transfection procedure (r 2 = 0.90).
BacMam compares favorably to transfection in dose-response assays
To examine the utility of BacMam in dose-response assays, BacMam-GR and BacMam-PR-B were characterized with a series of compounds previously profiled in reporter assays. The compounds selected included classic agonists such as progesterone for PR as well as several synthetic ligands that previously displayed varying degrees of potency and efficacy. T47D cells were cotransduced with receptor virus (50 virus particles per cell) and reporter virus (200 virus particles per cell), and cells were seeded onto duplicate 384-well plates containing serially diluted compounds. We observed similar compound activity between BacMam-transduced T47D cells and cells transfected with plasmid DNA; in addition, results were similar for compounds that were inactive or otherwise beyond the limit of detection (pEC 50 < 5). A comparison of potency values from BacMam and transfection studies with GR is presented in Table 1 . Dose- response curves for BacMam-PR-B assays in agonist (Fig. 3A) and antagonist (Fig. 3B ) modes are presented to illustrate general assay robustness. As with GR, BacMam-PR-B transduction resulted in compound potency and efficacy values similar to our previous results using DNA transfection (data not shown).
System efficacy is independent of receptor/reporter viral ratio but dependent on transduction time
To determine optimal assay conditions and to study the flexibility of BacMam transduction with the steroid nuclear receptors, we examined the effects of the virus/cell ratio in T47D and CV-1 cells. . These viral ratios demonstrated little or no effect on the S/B ratio in agonist mode experiments (Fig. 4) . Although MR (Fig. 4A) showed a moderate increase (6-to 10-fold) in signal over basal levels with increasing amounts of receptor, GR (Fig. 4B ) and PR-B (Fig. 4C Response values of test compounds were calculated as a percentage of controls 1 µM progesterone (normalized to 100%) and DMSO (normalized to 0%). Thus, the response in the presence of DMSO (0%) represents baseline, and 100% is equivalent to the response observed in the presence of the saturating concentration of progesterone. (B) Analysis of 3 antagonist compounds. Graphs represent the ability of test compounds to antagonize progesterone-stimulated transactivation. T47D cells were transduced in media supplemented with progesterone at its EC 80 and immediately distributed to assay plates containing serially diluted test compounds. Response values of compounds were calculated as a percentage of controls DMSO (normalized to 100%) and full-antagonist mifepristone (normalized to 0%). Thus, for antagonist mode assays, 0% represents complete inhibition of the progesterone-mediated agonist response, and 100% is equivalent to the response observed in the presence of DMSO and the EC 80 of progesterone (4 nM).
producible pEC 50 values, regardless of the receptor/reporter ratio ( Table 2) .
We examined the effect on S/B of varied receptor/reporter ratios in CV-1 cells transduced with PR-B. As seen in T47D cells (Fig. 4C) , we observed no appreciable effect on S/B by varying receptor/reporter ratios. However, from these experiments, we found that an increase in transduction time from 24 to 48 h negatively affected the S/B and Z′ values (Table 3 ). For CV-1 cells, a drop in S/B from approximately 20-fold for 24-h transductions to 6-fold for 48-h transductions correlated with a drop in Z′ value from 0.7 to 0.3. For T47D cells, a drop in S/B from approximately 6-fold for 24-h transductions to < 2-fold for 48-h transductions correlated with a drop in Z′ value from 0.6 to < 0.1. The diminution in assay robustness was evident in dose-response curves showing larger error bars for assays performed 48 h posttransduction (Fig.  5) . All other studies with BacMam constructs were performed with 24-h transduction procedures and consistently resulted in Z′ values of 0.5 to 0.7.
Correlation of PR isoforms demonstrates utility of BacMam
The BacMam technology was employed in an evaluation of the 2 PR isoforms that demonstrate pronounced functional differences in vivo despite their structural similarity. 32 We wished to better understand the comparative responses of PR-A and PR-B to a series of known agonists of PR-B having a broad potency range. In particular, we sought to determine if the pharmacology of PR-A and PR-B is different in the context of the reporter assays and if the distinct biological endpoints of PR-A and PR-B may ultimately be driven by divergent pharmacology. demonstrated similar responses of PR-A and PR-B in these assays (Fig. 6 ).
To ensure the integrity of PR-A and PR-B BacMam constructs, we analyzed their expression in human U-2OS osteosarcoma cells by Western blotting (Fig. 7) . Based on prior studies in our laboratory showing high transduction levels in U-2OS, these cells were selected for the expression studies. Western blot analysis demonstrated bands of expected sizes for PR-A (82 kDa) and PR-B (99 kDa). An additional band (80 kDa) of lower intensity was also observed for PR-B transductions, possibly resulting from proteolytic cleavage, although this was not confirmed. These results are consistent with previous reports demonstrating additional bands on Western blots probed with PR antibodies.
33,34
DISCUSSION
With a goal of developing flexible and robust cell-based assays for steroid nuclear receptor reporter assays, we exploited a recombinant baculovirus-based gene transfer strategy. A previous study using human estrogen receptor BacMam constructs demonstrated functionally identical responses to transfection of cells treated with tamoxifen and raloxifene. 26 We extended these results to steroid receptors MR, GR, PR-A, and PR-B, characterizing these BacMam constructs in a compound-screening environment. In this setting, there are several incentives for identifying a suitable alternative to standard transfection procedures. In particular, the BacMam sys- tem offered reductions in manual procedural steps, assay turnaround time, and cost. The feasibility of running BacMam screening assays was demonstrated in single-dose experiments with MR using an MMTVLuc reporter. We observed high correlation between BacMam transduction and FuGENE-based transfection procedures for more than 1000 compounds. Dose-response experiments using BacMam viruses for GR and PR-B also demonstrated high similarity with transfection-based assay results. In addition, a series of PR antagonists demonstrated pIC 50 and percentage inhibition values comparable to previous DNA transfection results. These findings agree with our previous observations with antagonist mode BacMam assays for estrogen receptors α and β using a BacMam estrogen response element-firefly luciferase reporter in T47D cells (RMK, JHP, and WCC, unpublished results).
Robust results were generated using the BacMam system. Low intra-assay variability was demonstrated by good Z′ values. Low interassay variability was indicated by low standard deviations of potency values between experiments for compounds with potency ranges over 2 log units. Compounds tested included partial and full agonists as well as known antagonists. A subset of compounds fell outside the limit of detection for both the transfection and BacMam assays, showing no discernable activity in agonist mode (pEC 50 < 5). Although factors such as solubility and toxicity can complicate interpretation of screening data for individual compounds, our overall results suggest that the BacMam technology may serve as a suitable substitute for transient transfection procedures, resulting in comparable hit rates in single concentration screens and similar activity profiles in dose-response experiments. Furthermore, we have observed similar compound activity profiles with BacMam assays for PR-B and GR in T47D cells in comparison to T47D stable reporter cell assays for these same receptors (RMK, unpublished results). Thus, the BacMam technology also produces cells reflecting with fidelity the responses of endogenously expressed receptors. 
